Related Experiment Videos
T-cell adjuvants
1Department of Internal Medicine, University of South Florida Medical College, Tampa 33612.
International Journal of Immunopharmacology
|September 1, 1994
Summary
This study explores T-cell adjuvants that enhance delayed type hypersensitivity (DTH) responses. New strategies, including interleukins and thymomimetic peptides, show promise for treating cancer and HIV.
Area of Science:
- Immunology
- Vaccinology
Background:
- Traditional adjuvants lack selectivity in stimulating T-cell mediated immunity.
- Natural infections and early experimental adjuvants like low-dose cyclophosphamide (CY) with mycobacteria demonstrated T-cell adjuvancy.
Purpose of the Study:
- To review advancements in T-cell adjuvancy for enhancing delayed type hypersensitivity (DTH).
- To highlight novel strategies for augmenting T-helper 1 (TH-1) responses and their therapeutic implications.
Main Methods:
- Review of existing literature on T-cell adjuvants and immune response modulation.
- Discussion of new adjuvant formulations, including synthetic T-cell epitopes.
- Exploration of cytokine-based therapies (IL-2, IL-12, gamma IFN) and gene transfection approaches.
Main Results:
- New adjuvant formulations (ISCOMS, MAPS) offer improved delivery of T-cell epitopes.
- Upregulation of TH-1 cells via interleukins or cytokine antibodies enhances pathogen and tumor resistance.
- Gene transfection of tumor cells with immune-stimulating genes presents novel therapeutic avenues.
Conclusions:
- Novel T-cell adjuvants and immunomodulatory strategies are crucial for enhancing TH-1 and DTH responses.
- These approaches hold significant potential for new treatment strategies against cancer and infections like HIV.
- Thymomimetic peptides and specific drug combinations may further augment cell-mediated immunity.